S B R T
I N D I C A T I O N S , B E N E F I T S A N D T O X I C I T I E S
Dr Bala Vellayappan
MBBS, FRANZCR, MCI
Consultant Radiation Oncologist
NCIS
S B R T
H I S T O R I C A L P E R S P E C T I V E
1951 : Lars Leksell - Gamma knife
1990s: Lax and Blomgren - Extra-cranial SBRT
@ Karolinska Institute
2000 : Uematsu - CT-guided lung SBRT
2010 : Bob Timmerman - RTOG 0236 published
S B R T
S T E R E O T A C T I C B O D Y R A D I A T I O N T H E R A P Y
Crossfire
S B R T
F R A C T I O N S I Z E
2 Gy 18 Gy
A D V A N T A G E S O V E R C O N V E N T I O N A L R T
Delivered over fewer fractions
Less disruption to chemotherapy
Higher success rates
Lower risks/SE
S B R T
3 B E N E F I T S F O R M E D O N C S T O R E M E M B E R A B O U T
1. Exceptional local control
2. Extremely convenient
3. Non-invasive ablation
S B R T
3 I N D I C A T I O N S O F
Early stage, medically inoperable : scapel-less surgery
Re-treatment
Oligomets : “local cure”
S B R T
W H A T W E C A N T R E A T W I T H
2. Metastases
Brain
Liver
Adrenal
Bone/Spine
1. Primary
Lung
Liver
Kidney
Prostate
3. Local recurrence
S B R T
R E S U L T S
In general, local control rates are 80 - 90 %
Depends on plan quality, dose delivered and
compromises taken
Lee P, IJROBP 2019 Apr
Ohri IJROBP 2018 p1
A L L P R E S C R I P T I O N S A R E N O T
E Q U A L
S B R T
A D O U B L E E D G E D S W O R D
S B R T
T O X I C I T I E S O F
Generally well-tolerated
Acute toxicity generally less than
conventional RT/chemoRT
Serious late toxicity is rare
T O X I C I T Y
D E P E N D S O N
P R O X I M I T Y
• Adjacent to hollow viscus
(trachea, GI tract)
• Abutting neural structures
(spinal cord, brachial
plexus etc)
• Volume effect
Chang JTO 2015 p577
Chang JTO 2015 p577
S B R T
F L Y W I T H C A U T I O N Z O N E F O R
SITE FEARED TOXICITY MITIGATING FACTORS
ESTIMATED
RATES
B R A I N R A D I O N E C R O S I S
S I Z E O F L E S I O N
F R A C T I O N A TI O N
5 - 1 0 %
B R A I N O P T I C N E R V E I N J U R Y
M A R G I N B E T W E E N 2 S T R U C T U R E S
F R A C T I O N A TI O N
< 1 %
L U N G T R A C H E A L I N J U R Y
> 2 C M S A F E T Y M A R G I N
F R A C T I O N A TI O N
< 5 %
L U N G P N E U M O N I T I S
D O S E - V O L U M E E F F E C T
N O I L D
< 5 %
L I V E R R I L D S P A R E E N O U G H N O R M A L L I V E R ( 7 0 0 C C ) < 5 %
L I V E R B O W E L I N J U R Y > 1 C M S A F E T Y M A R G I N < 5 %
S P I N E
V E R T E B R A L
C O M P R E S S I O N #
P R O P H Y L A T I C F I X A T I O N I F U N S T A B L E
F R A C T I O N A TI O N
1 0 %
S P I N E M Y E L O P A T H Y S A F E T Y M A R G I N O F 2 - 3 M M < 1 %
S B R T
S T E R E O T A C T I C B O D Y R A D I A T I O N T H E R A P Y - C O N C L U S I O N
High precision, Conformal
Short down time (i.e. more chemo)
Excellent local control
Safe in the right hands
One kick at the can - get it right
T H A N K Y O U
bala_vellayappan@nuhs.edu.sg

SBRT benefits and toxicities

  • 1.
    S B RT I N D I C A T I O N S , B E N E F I T S A N D T O X I C I T I E S Dr Bala Vellayappan MBBS, FRANZCR, MCI Consultant Radiation Oncologist NCIS
  • 2.
    S B RT H I S T O R I C A L P E R S P E C T I V E 1951 : Lars Leksell - Gamma knife 1990s: Lax and Blomgren - Extra-cranial SBRT @ Karolinska Institute 2000 : Uematsu - CT-guided lung SBRT 2010 : Bob Timmerman - RTOG 0236 published
  • 3.
    S B RT S T E R E O T A C T I C B O D Y R A D I A T I O N T H E R A P Y Crossfire
  • 4.
    S B RT F R A C T I O N S I Z E 2 Gy 18 Gy
  • 5.
    A D VA N T A G E S O V E R C O N V E N T I O N A L R T Delivered over fewer fractions Less disruption to chemotherapy Higher success rates Lower risks/SE
  • 6.
    S B RT 3 B E N E F I T S F O R M E D O N C S T O R E M E M B E R A B O U T 1. Exceptional local control 2. Extremely convenient 3. Non-invasive ablation
  • 7.
    S B RT 3 I N D I C A T I O N S O F Early stage, medically inoperable : scapel-less surgery Re-treatment Oligomets : “local cure”
  • 8.
    S B RT W H A T W E C A N T R E A T W I T H 2. Metastases Brain Liver Adrenal Bone/Spine 1. Primary Lung Liver Kidney Prostate 3. Local recurrence
  • 9.
    S B RT R E S U L T S In general, local control rates are 80 - 90 % Depends on plan quality, dose delivered and compromises taken Lee P, IJROBP 2019 Apr Ohri IJROBP 2018 p1
  • 10.
    A L LP R E S C R I P T I O N S A R E N O T E Q U A L
  • 11.
    S B RT A D O U B L E E D G E D S W O R D
  • 12.
    S B RT T O X I C I T I E S O F Generally well-tolerated Acute toxicity generally less than conventional RT/chemoRT Serious late toxicity is rare
  • 13.
    T O XI C I T Y D E P E N D S O N P R O X I M I T Y • Adjacent to hollow viscus (trachea, GI tract) • Abutting neural structures (spinal cord, brachial plexus etc) • Volume effect
  • 14.
    Chang JTO 2015p577 Chang JTO 2015 p577 S B R T F L Y W I T H C A U T I O N Z O N E F O R
  • 16.
    SITE FEARED TOXICITYMITIGATING FACTORS ESTIMATED RATES B R A I N R A D I O N E C R O S I S S I Z E O F L E S I O N F R A C T I O N A TI O N 5 - 1 0 % B R A I N O P T I C N E R V E I N J U R Y M A R G I N B E T W E E N 2 S T R U C T U R E S F R A C T I O N A TI O N < 1 % L U N G T R A C H E A L I N J U R Y > 2 C M S A F E T Y M A R G I N F R A C T I O N A TI O N < 5 % L U N G P N E U M O N I T I S D O S E - V O L U M E E F F E C T N O I L D < 5 % L I V E R R I L D S P A R E E N O U G H N O R M A L L I V E R ( 7 0 0 C C ) < 5 % L I V E R B O W E L I N J U R Y > 1 C M S A F E T Y M A R G I N < 5 % S P I N E V E R T E B R A L C O M P R E S S I O N # P R O P H Y L A T I C F I X A T I O N I F U N S T A B L E F R A C T I O N A TI O N 1 0 % S P I N E M Y E L O P A T H Y S A F E T Y M A R G I N O F 2 - 3 M M < 1 %
  • 17.
    S B RT S T E R E O T A C T I C B O D Y R A D I A T I O N T H E R A P Y - C O N C L U S I O N High precision, Conformal Short down time (i.e. more chemo) Excellent local control Safe in the right hands One kick at the can - get it right
  • 18.
    T H AN K Y O U bala_vellayappan@nuhs.edu.sg

Editor's Notes

  • #6 Better patient satisfaction